

FireGate Biotech Inc.

News — October 2025

FireGate Update

Team Formation & Scientific Leadership Announcement

Opening the Curtain

FireGate Biotech began transitioning from a largely stealth development phase toward a more public-facing structure during October 2025. The company initiated early steps to introduce scientific leads and collaborators supporting discovery research and long-term translational planning.

People

Initial organizational efforts focused on establishing the scientific framework required to support the company's modular research programs and future collaboration with academic and industry partners.

Federal Eligibility — SAM.gov Active Registration

FireGate Biotech became an active entity within the federal contracting and grants ecosystem through registration in the System for Award Management (SAM.gov).

Compliance

FireGate Biotech is a SAM.gov-registered entity and is authorized to apply for federal research funding programs including:

- NIH SBIR / STTR programs
- ARPA-H research initiatives
- AFWERX innovation programs

FireGate is also registered as a **Veteran-Owned Small Business (VOSB)**, strengthening eligibility for innovation-aligned federal research opportunities.

Publications Launch — Triplet Platform Publications

October 2025 marked the initial public release of scientific materials describing the FireGate research framework.

Preprints

Initial scientific content describing the **Triplet Immunologic Modulation strategy** across infectious disease, oncology, and neuro-immune biology was made publicly available.

Future data releases and supporting materials will be shared through the FireGate Division of Research (FGD) portal.

Operational & Strategic Highlights

Program Notes

- **FG-003:** Announced the FG-003 neuro-immune repair initiative as the third program within the FireGate triplet research platform.

About FireGate Biotech Inc.

FireGate Biotech Inc. is a veteran-founded biotechnology company developing modular, triplet-directed research programs across infectious disease, oncology, and neuro-immune biology.

The company's research pipeline includes three core initiatives:

- FG-001 — HIV
- FG-002 — Oncology Viral Mimicry
- FG-003 — Neuro-Immune Repair

Website:

<https://firegatebiotech.com>